886679-04-5

Basic information

• Product Name: 4-Benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide
• Synonyms: 4-Benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide
• CAS NO: 886679-04-5
• Molecular Weight: 401.508
• Mol File: 886679-04-5.mol

Chemical Properties

• CAS DataBase Reference: 4-Benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide(886679-04-5)
• EPA Substance Registry System: 4-Benzhydryl-N-(4-methoxyphenyl)piperazine-1-carboxamide(886679-04-5)

Safety Data

• Hazardous Substances Data: 886679-04-5(Hazardous Substances Data)

Upstream product

• 104-94-9 4-methoxy-aniline 
• 13521-97-6 (4-benzhydrylpiperazin-1-yl)carbonyl chloride 
• 841-77-0 diphenylmethylpiperazine 

Relevant articles and documents

Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)

The key hydrolytic enzymes of the endocannabinoid system, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), are potential targets for various therapeutic applications. In this paper, we present more extensively the results of our previous work on piperazine and piperidine carboxamides and carbamates as FAAH and MAGL inhibitors. The best compounds of these series function as potent and selective MAGL/FAAH inhibitors or as dual FAAH/MAGL inhibitors at nanomolar concentrations. This study revealed that MAGL inhibitors should comprise leaving-groups with a conjugate acid pKa of 8-10, while diverse leaving groups are tolerated for FAAH inhibitors.

NON-PEPTIDIC NEUROPEPTIDE Y RECEPTOR MODULATORS

The invention provides compounds that are modulators of neuropeptide Y (NPY) receptors, which can be selective inhibitors of NPY receptor Y2R. NPY receptor modulatory compounds are of the general formula Ar2-Y-Ar1-W-Ar3, wherein the variables are as defined herein. Compounds of the invention can be used for treatment of malconditions in patients wherein modulation of an NPY receptor is medically indicated, for example including drug or alcohol abuse, anxiety disorders, depression, stress-related disorders, neurological disorders, nerve degeneration, osteoporosis or bone loss, sleep/wake disorders, cardiovascular diseases, obesity, anorexia, inovulation, fertility disorders, angiogenesis, cell proliferation, learning and memory disorders, migraine and pain.